Welcome to LookChem.com Sign In|Join Free
  • or
(2R,3R,4S,5R)-2-(6-amino-8-((4-fluorobenzyl)amino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

402725-52-4

Post Buying Request

402725-52-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

402725-52-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 402725-52-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,2,7,2 and 5 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 402725-52:
(8*4)+(7*0)+(6*2)+(5*7)+(4*2)+(3*5)+(2*5)+(1*2)=114
114 % 10 = 4
So 402725-52-4 is a valid CAS Registry Number.

402725-52-4Downstream Products

402725-52-4Relevant academic research and scientific papers

Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70

Cheeseman, Matthew D.,Westwood, Isaac M.,Barbeau, Olivier,Rowlands, Martin,Dobson, Sarah,Jones, Alan M.,Jeganathan, Fiona,Burke, Rosemary,Kadi, Nadia,Workman, Paul,Collins, Ian,Van Montfort, Rob L. M.,Jones, Keith

, p. 4625 - 4636 (2016)

HSP70 is a molecular chaperone and a key component of the heat-shock response. Because of its proposed importance in oncology, this protein has become a popular target for drug discovery, efforts which have as yet brought little success. This study demonstrates that adenosine-derived HSP70 inhibitors potentially bind to the protein with a novel mechanism of action, the stabilization by desolvation of an intramolecular salt-bridge which induces a conformational change in the protein, leading to high affinity ligands. We also demonstrate that through the application of this mechanism, adenosine-derived HSP70 inhibitors can be optimized in a rational manner.

Anti-HCV nucleoside derivatives

-

, (2008/06/13)

The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 402725-52-4